ImmuneOnco Reports HKD 0.16 Million Share Buy-back; Treasury Shares Rise to 2.07 Million

Bulletin Express

Sep 04

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. disclosed a new share repurchase on 4 September 2026 under its existing mandate, buying back 44,800 H shares on the Hong Kong Stock Exchange.

Key transaction details • Volume: 44,800 H shares, representing 0.0107% of ImmuneOnco’s outstanding shares prior to the transaction. • Price range: HKD 3.435–3.550 per share; volume-weighted average price of HKD 3.4693. • Cash outlay: HKD 0.16 million.

Share capital movement • Issued shares (ex-treasury) decreased to 418.41 million from 418.46 million. • Treasury shares increased to 2.07 million from 2.02 million. • Total issued shares remained unchanged at 420.48 million.

Repurchase mandate status • Authorised limit: 43.15 million shares (shareholders’ resolution dated 28 May 2026). • Cumulative repurchases under the mandate: 2.07 million shares, equal to 0.48% of the share count on the mandate date. • A 30-day moratorium on new share issues or treasury share sales is in effect until 4 October 2026.

All repurchases complied with Hong Kong Listing Rules and the company’s mandate requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/news/1145259717"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145259717\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145259717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-04 18:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145259717","market":"us","top_or_hot":-1,"title":"ImmuneOnco Reports HKD 0.16 Million Share Buy-back; Treasury Shares Rise to 2.07 Million","media":"Bulletin Express","content":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. disclosed a new share repurchase on 4 September 2026 under its existing mandate, buying back 44,800 H shares on the Hong Kong Stock Exchange.</p>\n<p>Key transaction details  \n• Volume: 44,800 H shares, representing 0.0107% of ImmuneOnco’s outstanding shares prior to the transaction.  \n• Price range: HKD 3.435–3.550 per share; volume-weighted average price of HKD 3.4693.  \n• Cash outlay: HKD 0.16 million.</p>\n<p>Share capital movement  \n• Issued shares (ex-treasury) decreased to 418.41 million from 418.46 million.  \n• Treasury shares increased to 2.07 million from 2.02 million.  \n• Total issued shares remained unchanged at 420.48 million.</p>\n<p>Repurchase mandate status  \n• Authorised limit: 43.15 million shares (shareholders’ resolution dated 28 May 2026).  \n• Cumulative repurchases under the mandate: 2.07 million shares, equal to 0.48% of the share count on the mandate date.  \n• A 30-day moratorium on new share issues or treasury share sales is in effect until 4 October 2026.</p>\n<p>All repurchases complied with Hong Kong Listing Rules and the company’s mandate requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco Reports HKD 0.16 Million Share Buy-back; Treasury Shares Rise to 2.07 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco Reports HKD 0.16 Million Share Buy-back; Treasury Shares Rise to 2.07 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-04 18:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. disclosed a new share repurchase on 4 September 2026 under its existing mandate, buying back 44,800 H shares on the Hong Kong Stock Exchange.</p>\n<p>Key transaction details  \n• Volume: 44,800 H shares, representing 0.0107% of ImmuneOnco’s outstanding shares prior to the transaction.  \n• Price range: HKD 3.435–3.550 per share; volume-weighted average price of HKD 3.4693.  \n• Cash outlay: HKD 0.16 million.</p>\n<p>Share capital movement  \n• Issued shares (ex-treasury) decreased to 418.41 million from 418.46 million.  \n• Treasury shares increased to 2.07 million from 2.02 million.  \n• Total issued shares remained unchanged at 420.48 million.</p>\n<p>Repurchase mandate status  \n• Authorised limit: 43.15 million shares (shareholders’ resolution dated 28 May 2026).  \n• Cumulative repurchases under the mandate: 2.07 million shares, equal to 0.48% of the share count on the mandate date.  \n• A 30-day moratorium on new share issues or treasury share sales is in effect until 4 October 2026.</p>\n<p>All repurchases complied with Hong Kong Listing Rules and the company’s mandate requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1145259717","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145259717","pubTimestamp":1788518510,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. disclosed a new share repurchase on 4 September 2026 under its existing mandate, buying back 44,800 H shares on the Hong Kong Stock Exchange. Key...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"ImmuneOnco 报告回购 16 万港元股票；库存股增至207万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. disclosed a new share repurchase on 4 September 2026 under its existing mandate, buying back 44,800 H shares on the Hong Kong Stock Exchange.\nKey transaction details  \n• Volume: 44,800 H shares, representing 0.0107% of ImmuneOnco’s outstanding shares prior to the transaction.  \n• Price range: HKD 3.435–3.550 per share; volume-weighted average price of HKD 3.4693.  \n• Cash outlay: HKD 0.16 million.\nShare capital movement  \n• Issued shares (ex-treasury) decreased to 418.41 million from 418.46 million.  \n• Treasury shares increased to 2.07 million from 2.02 million.  \n• Total issued shares remained unchanged at 420.48 million.\nRepurchase mandate status  \n• Authorised limit: 43.15 million shares (shareholders’ resolution dated 28 May 2026).  \n• Cumulative repurchases under the mandate: 2.07 million shares, equal to 0.48% of the share count on the mandate date.  \n• A 30-day moratorium on new share issues or treasury share sales is in effect until 4 October 2026.\nAll repurchases complied with Hong Kong Listing Rules and the company’s mandate requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}